Synapticure’s Origin Story: Our Mission, Milestones, and Impact

In 2017, Brian Wallach was diagnosed with ALS at just 37 years old. Like so many families facing neurodegenerative disease, Brian and his wife, Sandra Abrevaya, were given a devastating prognosis, but no clear path forward. Instead of receiving clear guidance and support, they were left to navigate an overwhelming, complex, and fragmented healthcare system on their own, struggling to find the right doctors, treatments, and clinical trials.

That moment, that heartbreak, became the foundation of Synapticure.

Synapticure was born from urgency, built on empathy, and driven by a belief that patients and caregivers deserve a proactive and compassionate approach to care. Today, we are revolutionizing neurological care from the ground up—through a virtual-first model that offers fast access to expert neurologists, coordinated care, cutting-edge clinical trials and treatments, and the kind of compassionate support Brian and Sandra wished existed years ago.

We’re building more than a company; we’re building the kind of care system we wish every family had access to.

‍

‍

Our Mission

Synapticure exists to improve outcomes and quality of life for people living with neurodegenerative diseases. We combine world-class clinical expertise with a virtual-first model that removes barriers to access, speeds up time to treatment, and surrounds families with a care team that sees them, knows them, and stays with them throughout their journey.

There are over 10 million Americans currently living with ALS, Parkinson’s, Alzheimer’s, dementia, Huntington’s disease, and other neurodegenerative conditions. As the U.S. population ages, these numbers will only continue to grow. And yet, access to expert care remains limited– especially outside of major metro areas. 

Across the country, families face neurologist shortages, long wait times, fragmented care, and slow access to treatments—making it harder to get the care they need, when they need it.

That’s where Synapticure comes in.

‍

‍

Our Innovative Care Model

Synapticure’s innovative model is built on three pillars:

• Fast access to comprehensive, expert-led care and support
• Navigation to clinical trials
• Acceleration of research

Each pillar reinforces the others, creating a cycle of care that delivers better outcomes for patients while advancing the science that could save lives.

Licensed in all 50 states, Synapticure brings together a team of expert neurologists, subspecialists, genetic counselors, mental health providers, care coordinators, and wraparound services to provide personalized, comprehensive care for every stage of a neurodegenerative disease.

With one click, a person living with ALS in rural Montana or a caregiver in downtown Seattle can get support. No long waits. No fragmented referrals. No family burden to coordinate care, navigate the system, or find resources. Just fast, expert-led, personalized care– in collaboration with existing doctors and local clinics or as a complete care team. 

And it's working.

• We provide fast access to expert care, instead of 6+ month wait times. 
• Patients visit the ER 19% less compared to traditional models. 
• 30% of patients report reduced anxiety and 28% report reduced depression, thanks to our integrated behavioral health program.
• Families in underserved and rural areas have access to expert care and treatment. 
• Patients receive help navigating and connecting to clinical trials across the nation 

Caregivers receive much-needed support including care coordination, insurance navigation, mental health support, and connections to local in-home services to reduce the burden and focus on what really matters– their loved ones.

‍

‍

Our Journey So Far

Synapticure’s story began with Brian Wallach, Sandra Abrevaya, and Pete Wallach, whose personal mission to democratize access to expert care, promising treatments, and clinical trials quickly grew into a movement for change.

After launching in February 2022 with a deeply personal feature in The New York Times, Synapticure set out to rewrite the playbook for neurological care, starting with ALS. We knew from experience that patients and caregivers needed faster access, clearer pathways, and a team they could trust. So we built it.

In 2022, we welcomed Dr. Eric Anderson, a nationally recognized neurologist, as our Chief Medical Officer, deepening our clinical leadership and strengthening our foundation. By November, our innovative model was proving its impact and we expanded to support patients with Parkinson’s and Huntington’s disease. 

In 2023, we became fully licensed in all 50 states, allowing us to support patients across the nation, wherever they call home. 

Throughout 2023, our growth accelerated. We launched an IRB-approved study to provide proactive care for presymptomatic ALS gene carriers in April, and by November, we had expanded our services to cognitive care. Recognizing the emotional burden of these diseases on both patients and their families, we launched our Collaborative Mental Health Program in December 2023 to bring therapy and behavioral health services to both patients and caregivers.

In 2024, our momentum continued. Our 3D cell model research was featured on the cover of Stem Cell Reports, with multiple publications becoming among the journal’s most cited. We were awarded an NIH grant to advance our therapeutic discovery work and launched the first fully virtual clinical trial through Clene’s Expanded Access Program. That same year, we were selected as the only nationwide provider for the CMS GUIDE model.

In November, we closed a $25 million Series A fund to serve even more families across the United States and our CEO and co-founder, Sandra Abrevaya, was named one of Entrepreneur’s Top 20 Innovative Leaders—recognizing her work to revolutionize healthcare. 

Now in 2025, our results are beginning to speak for themselves. In April, early outcomes from our Collaborative Mental Health Program showed a significant reduction in anxiety and depression, along with improved quality of life for our patients. In June, we received a $2.5M SBIR grant from the National Institute of Neurological Disorders and Stroke to extend our cell model research for Frontotemporal Dementia (FTD), ALS, and Alzheimer’s—helping advance research even further for our patients.

‍

‍

The Road Ahead

We believe care should meet people where they are, and no family should be left to navigate a diagnosis alone. At Synapticure, we’re not just changing how care is delivered. We’re building a system that offers real guidance, expert support, and a clear path forward when it matters most by putting families at the center of care.

If you're living with a neurodegenerative disease, or caring for someone who is, you shouldn't have to navigate it alone. We're here to help.